Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.43 |
| ▸ | JAK3 | P52333 | 15/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 8/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935107 | 0.82 | IL1B (0.47) | — | |
| SCHEMBL935451 | 0.81 | IDO1 (0.39) | — | |
| SCHEMBL935236 | 0.76 | PIM1 (0.46) | JAK3 | |
| SCHEMBL993295 | 0.76 | CDC7 (0.70) | JAK2JAK3 | |
| SCHEMBL935927 | 0.76 | JAK2 (0.52) | JAK2JAK3JAK1 | |
| SCHEMBL936047 | 0.75 | KMT2A (0.53) | — | |
| SCHEMBL935824 | 0.74 | USP30 (0.46) | CNR1CNR2 | |
| SCHEMBL17196752 | 0.71 | JAK2 (0.62) | JAK2JAK3JAK1 | |
| SCHEMBL17196850 | 0.71 | JAK2 (0.62) | JAK2JAK3JAK1 | |
| SCHEMBL1045762 | 0.71 | CDC7 (0.36) | JAK3CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383624-B2 | Pyrrolopyrazine inhibitors of kinases | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2454262-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2011008830-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | JAK2 356/4885JAK3 469/4885CYP11B1 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.